Skip to Content

Trials of New Cancer Therapies Can’t Enroll Enough Patients

August 14, 2017

Engineering of human immune cells to fight off cancer promised to help cure the disease, and, so far, it appears to be living up to the hype. So you might think that enlisting patients to take part in trials of the new therapies would be easy. But the New York Times reports that there's a hitch. First, many biotech firms are creating similar and competing treatments. Second, they can't be offered to all patients, perhaps because their cancers are treated surgically or because they don't attend a hospital involved with research. Combined, those factors mean that many trials are failing to recruit enough people to obtain useful results—and it's even worse for targeted therapies.

Deep Dive


Our best illustrations of 2022

Our artists’ thought-provoking, playful creations bring our stories to life, often saying more with an image than words ever could.

How CRISPR is making farmed animals bigger, stronger, and healthier

These gene-edited fish, pigs, and other animals could soon be on the menu.

The Download: the Saudi sci-fi megacity, and sleeping babies’ brains

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. These exclusive satellite images show Saudi Arabia’s sci-fi megacity is well underway In early 2021, Crown Prince Mohammed bin Salman of Saudi Arabia announced The Line: a “civilizational revolution” that would house up…

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.